BCL11A and Schnyder corneal dystrophy: Globally, 10 preliminary clinical results have been reported from three clinical trials (NCT03655678, NCT04211480, NCT04925206) which used the CRISPR technology to target BCL11A +58 enhancer for the treatment of SCD or β-thalassemia.